Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis
暂无分享,去创建一个
[1] G. Guyatt,et al. A living WHO guideline on drugs for covid-19 , 2022, BMJ.
[2] Steve B Jones,et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, Lancet.
[3] X. Mariette,et al. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider , 2021, Annals of the Rheumatic Diseases.
[4] A. Zangrillo,et al. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. , 2021, European Journal of Internal Medicine.
[5] L. Valsecchi,et al. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study , 2021, The Journal of Immunology.
[6] F. Montorsi,et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study , 2021, The Lancet Rheumatology.
[7] J. Timsit,et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case–cohort study from the multicentric OUTCOMEREA network , 2021, Intensive Care Medicine.
[8] E. Vicaut,et al. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial , 2021, The Lancet Respiratory Medicine.
[9] G. Cavalli,et al. Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and targeted treatment of autoimmune and inflammatory diseases. , 2021, Autoimmunity reviews.
[10] Christopher M. Horvat,et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 - Preliminary report , 2021, medRxiv.
[11] Y. Hu,et al. [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.
[12] C. June,et al. Cytokine Storm , 2020, The New England journal of medicine.
[13] G. Guyatt,et al. Remdesivir for severe covid-19: a clinical practice guideline , 2020, BMJ.
[14] M. Cesari,et al. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study , 2020, Journal of Allergy and Clinical Immunology.
[15] I. Al-Zakwani,et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study , 2020, International Journal of Infectious Diseases.
[16] M. Netea,et al. An open label trial of anakinra to prevent respiratory failure in COVID-19 , 2020, medRxiv.
[17] L. Coates,et al. Antirheumatic Disease Therapies for the Treatment of COVID‐19: A Systematic Review and Meta‐Analysis , 2020, Arthritis & rheumatology.
[18] C. Dinarello,et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19 , 2020, Proceedings of the National Academy of Sciences.
[19] S. Bhagani,et al. Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series , 2020, Rheumatology advances in practice.
[20] M. Crow,et al. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series , 2020, Arthritis & rheumatology.
[21] Jennifer L. Bell,et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.
[22] M. An,et al. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis , 2020, medRxiv.
[23] G. Chatellier,et al. Anakinra for severe forms of COVID-19: a cohort study , 2020, The Lancet Rheumatology.
[24] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[25] G. Antonucci,et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease , 2020, Journal of Allergy and Clinical Immunology.
[26] A. Zangrillo,et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.
[27] E. Bergot,et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series , 2020, Annals of the Rheumatic Diseases.
[28] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[29] T. Jodlowski,et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.
[30] E. Gertner,et al. Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation Syndrome , 2020, ACR open rheumatology.
[31] S. Merler,et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.
[32] C. Eastin,et al. Characteristics and Outcomes of 21 Critically Ill Patients with COVID-19 in Washington State , 2020, The Journal of Emergency Medicine.
[33] Mei U Wong,et al. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning , 2020, bioRxiv.
[34] G. Remuzzi,et al. COVID-19 and Italy: what next? , 2020, The Lancet.
[35] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[36] Ting Yu,et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.
[37] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[38] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[39] R. Cron,et al. Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis , 2020, Arthritis & rheumatology.
[40] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[41] Natalie S Blencowe,et al. RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.
[42] Carrie D. Patnode,et al. Recommendations for assessing the risk of bias in systematic reviews of health-care interventions. , 2017, Journal of clinical epidemiology.
[43] Richard L. Amdur,et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial* , 2016, Critical care medicine.
[44] G. Cavalli,et al. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. , 2015, Rheumatology.
[45] D. Moher,et al. Preferred reporting items of systematic review and meta-analyses: the PRISMA statement , 2011 .